澳大利亚亚洲淋巴瘤联盟及合作者开展的原发性玻璃体视网膜淋巴瘤国际真实世界研究
这项国际多中心回顾性队列研究纳入2010至2022年间来自澳大利亚、新加坡、加拿大和英国11个中心的60例原发性玻璃体视网膜淋巴瘤患者,描述真实世界诊疗实践与结局。总体缓解率78%,中位随访68个月,中位无进展生存25个月、中位总生存73个月;5年中枢神经系统复发累积发生率33%,一线全身治疗是中枢神经系统复发的唯一预测因素(HR 0.30,95%CI 0.09-0.98,p=0.05)。
要点
- 多数患者(63%)初始管理包含全身治疗,13%接受 upfront 自体干细胞移植。
- 中位无进展生存25个月,中位总生存73个月,总体缓解率78%。
- 5年中枢神经系统复发累积发生率为33%,一线全身治疗是唯一预测因素(HR 0.30)。
核心结论
- 真实世界中原发性玻璃体视网膜淋巴瘤的诊断、分期和管理方法存在异质性,需要进一步国际合作以解决这一罕见疾病的未满足需求。
- 将全身治疗纳入初始治疗或 upfront 自体干细胞移植均未显示对无进展生存或总生存有统计学显著影响。
研究设计与样本
- 国际多中心回顾性队列研究,纳入2010至2022年间来自澳大利亚、新加坡、加拿大和英国11个中心的60例原发性玻璃体视网膜淋巴瘤患者。
主要发现
- 多数患者(63%)初始管理包含全身治疗,单独或联合局部治疗;13%接受 upfront 自体干细胞移植。
- 总体缓解率为78%。
- 中位随访68个月,中位无进展生存为25个月,中位总生存为73个月。
- 将全身治疗纳入初始治疗或 upfront 自体干细胞移植均未显示对无进展生存或总生存有统计学显著影响。
- 5年中枢神经系统复发累积发生率为33%,多变量模型中一线全身治疗是中枢神经系统复发的唯一预测因素,风险比0.30(95%CI 0.09-0.98,p=0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary vitreoretinal lymphoma (PVRL) is a high-grade extranodal non-Hodgkin lymphoma, with limited prospective data to inform practice. High rates of central nervous system (CNS) relapse contribute to its poor prognosis. This international multicentre retrospective cohort study aimed to characterise real-world contemporary practice and outcomes in PVRL (2010-2022). Sixty patients were included from 11 centres across Australia, Singapore, Canada and the United Kingdom. Most patients had systemic therapy included in their initial management (63%) either alone or in combination with local therapies; 13% had upfront autologous stem cell transplantation (ASCT). The overall response rate was 78%. With a median follow-up of 68 months, the median progression-free survival (PFS) was 25 months, with a median overall survival (OS) of 73 months. Neither incorporation of systemic therapy into initial treatment nor upfront ASCT demonstrated a statistically significant impact on PFS or OS. The 5-year cumulative incidence of CNS relapse was 33%, with front-line systemic therapy being the only predictive factor for CNS relapse in a multivariate model, hazard ratio of 0.30 (95% CI 0.09-0.98, p = 0.05). Concerning heterogeneity in real-world approaches to diagnosis, staging and management approaches were identified. Further international collaborative efforts are required to address the unmet need in this rare entity.
引用
- Tang C, Downie C, Sagoo MS, et al. An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaborators. Br J Haematol. 2025. PMID: 40328516. doi:10.1111/bjh.20115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。